Dezfoli S, McGarrity TJ, Rampertab SD.
Effectiveness of a Personal and Family History questionnaire When Assessing Colorectal Cancer Risk.
Practical Gastroenterology. March 2014:44-52. 

Yoo L, Mathew A, McGarrity TJ.
Removal of a Partially Prolapsing Intraductal Ampullary Adenoma.
Gastrointestinal Endoscopy, 2014:79(3):377. 

Tchekmedyian A, Amos CI, Bale SJ, Zhu D, Arold S, Berrueta J, Nabon N, McGarrity T.
Findings from the Peutz-Jeghers Syndrome Registry of Uruguay.
PloS One [Electronic Resource]. 2013;8(11):e79639.doi:10.1371/journal.pone.0079639. 

Welch A, McGarrity T, Mani H, Moyer M.
Cystic Neuroendocrine Tumor of the Pancreas: A Rare Type of Pancreatic cystic Lesion Accurately Diagnosed and Staged by EUS-FNA.
Practical Gastroenterology. October 2013:31-34. 

Bhardwaj A, Stairs DB, Mani H, McGarrity TJ.
Barrett's Esophagus: Emerging Knowledge and Management Strategies.
Patholog Res Int. 2012 

Poynard T, Munteanu M, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, SchmidtW, Berg T, McGarrity T, Heathcote EJ, Goncales F, Diago M, Craxi A, Silva M, Boparaai N., Griffel L, Burroughs M, Brass C. Albrecht J.
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program.
J Hepatol. 2011, 54(2):227-35. 

Mathew, A; Peiffer, LP; Rhoades, K; McGarrity, TJ.
Improvement in Quality of Life Measures in Patients with Refractory Hepatitis C, Responding to Retreatment with Pegylated Interferon Alpha-2b and Ribavirin.
Health and Quality of Life Outcomes 2006, 4:30. 

McGarrity, T. and Amos, C.
Less Common Colorectal Cancer Predisposition Syndromes.
Surgical Oncology Clinics of North America 2009, 18(4):647-661. 

Mukherjee, A., McGarrity, T., Staveley-O’Carroll, K., Ruggiero, F., and Baker, MJ.
Hereditary Diffuse Gastric Cancer: lifesaving potential of prophylactic gastrectomy
Community Oncology 2009;6:41-45. 

Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T. et al.
Peginterferon alfa-2b-Ribavirin: Effective in patients with hepatitis C who failed Interferon alfa/ribavirin.
Gastroenterology 2009;136(5):1618-28. 

Woo, A., Sadana, A., Mauger, D., Baker, M., Berk, T., McGarrity, T
Psychosocial Impact of Peutz-Jeghers Syndrome.
Familial Cancer 2009;8(1):59-65. 

Tobi M, Kam M, Ullah N, Qureshi K, Yordanova V, Hatfield J, Fligiel SEG, Sochacki P, McGarrity T, Cole C, Lawson M, Jacoby R.
An Anti-adenoma Antibody, Adnab-9, may reflect the risk for neoplastic progression in familial hamartomatous polyposis syndromes.
Dig Dis Sci 2008 (Mar);53(3):723-9 

Mathew, A., Peiffer L.P., Rhoades K., McGarrity, T.
Sustained Viral Response to Pegylated Interferon a-2b and Ribavirin in Chronic Hepatitis C Refractory to Prior Treatment.
Dig Dis Sci 2006; 51:1956-1961. 

McGarrity, T.J. and Amos, C.J.
Peutz-Jeghers syndrome: clinicopathology and molecular alterations.
Cellular and Molecular Life Sciences (CMLS) September 2006; Vol 63(18):2135-2144. 

Hobley, J; Lengerich, EJ; Lindsay JA II; McGarrity, TJ.
Disparities between Blacks and Whites in Stage at Diagnosis, Incidence, and Anatomic Subsite of Colorectal Center.
Gastroenterology & Hepatology July 2006; Vol 2(7):498-502. 

McGarrity, TJ, Amos, C.
Peutz-Jeghers Syndrome: Clinicopathology and Molecular Alterations.
Cellular and Molecular Life Sciences Sept 2006; 63(18):2135-44 

Mathew, A; Peiffer, LP; Rhoades, K; McGarrity, TJ.
Improvement in Quality of Life Measures in Patients with Refractory Hepatitis C, Responding to Retreatment with Pegylated Interferon Alpha-2b and Ribavirin.
Health and Quality of Life Outcomes 2006, 4:30 

Mathers B, Moyer M, Mathew A, Dye C, Levenick J, Gusani N, Dougherty-Hamod B, McGarrity, T.
Percutaneous Debridement and Washout of Walled-off Abdominal Abscess and Necrosis Using Flexible Endoscopy: A Large Single-center Experience.
Endoscopy Jan 2016: 4(1):E102-6. 

McGarrity TJ, Amos CI, Baker M.
Peutz-Jeghers Syndrome.
GeneReviews® 

Oluyemi AO, Welch AR, Yoo LJ, Lehman, EB, McGarrity TJ, Chuang CH.
Colorectal cancer screening in high-risk groups is increasing, although current smokers fall behind.
Cancer. 2014:120(14):2106-13. 

Elwir S, Sharzehi K, Veith J, Moyer MT, Dye C, McGarrity T, Mathew A.
Biliary stenting in patients with malignant biliary obstruction: comparison of double layer, plastic and metal stents.
Dig Dis Sci 2013;58(7):2088-92. 

Healthnet CRC screenings article, April 2013, “Colorectal Cancer Screenings:  A Provider’s Recommendation Can Make the Difference.”  
Available at https://www.hnfs.com/content/hnfs/home/tn/prov/provider_news/open-access-crc-screenings.html

Moole S, McGarrity TJ, Baker MJ.
Screening for Familial Colorectal Cancer Risk Amongst Colonoscopy Patients New to an Open Access Endoscopy Center.
ISRN Gastroenterology, 2012, Article ID 152980. 

McGarrity TJ, Gagliardi E.
Open Access Endoscopy: Increasing Access for Colorectal Cancer Screening.
Keystone Physician, Fall 2011:60-64. 

Mukherjee A, McGarrity TJ, Ruggiero F, Koltun W, McKenna K, Poritz L, Baker MJ.
The Revised Bethesda Guidelines: Extent of utilization in a University Hospital Medical Center with a Cancer Genetics Program.
Hereditary Cancer in Clinical Practice 2010;8:9. 

McGarrity TJ, Amos CI, Frazier ML, Wei C.  
Peutz-Jeghers Syndrome.  
In:  Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews® [Internet].  Seattle (WA):  University of Washington, Seattle; 1993-2014.  2001 Feb 23 [updated 2013 Jul 25].

Dominic OG, McGarrity T, Dignan M, Lengerich EJ.
American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008, Letter to the Editor.
Am J Gastroenterol 2009;2626-2627. 

McHutchison, JG, Lawitz, EJ, Shiffman, ML, et al.
for the IDEAL Study Team (McGarrity, TJ). Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection.
N Engl J Med 2009;361:580-93.

Visit PubMed to view publications prior to 2006.